Legal Drugs Podcast

Author: Angela Stoyanovitch

Every day, each of us is affected by legal drugs. The pharmaceutical industry is one of the strongest, richest and yet most mysterious industries in America. Why do some drugs make it to market and others don't? Why are some drugs so expensive? And what is the human effect of this industry? Join industry veteran Angela Stoyanovitch as she explores the complex systems in place and what it means for you and me.
Be a guest on this podcast

Language: en

Genres: Business News, Health & Fitness, Medicine, News

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Trailer:

Get all podcast data

Listen Now...

33. Investigating Cardiotoxicity in a 3-Drug Comparison for the Treatment of COVID19 with AnaBios's Dr. Najah Abi-Gerges
Monday, 19 July, 2021

In this episode, Legal Drugs Podcast Host, Angela Stoyanovitch, speaks with Dr. Najah Abi-Gerges, head of AnaBios Corporation's R&D. Najah walks the audience through recent publications in collaboration with big pharma on the cardiotoxicity effects of three drugs that have been posed to treat COVID19. Cardiotoxicity studies are an important step in understanding the safety of a legal drug. AnaBios uses their early-stage discovery and translational research model to test and compare Hydroxychloroquine, Chloroquine and Azithromycin in adult human primary cardiomyocytes. Cardio safety is especially personal to both Angela and Najah as both speak about their family history with heart disease. More importantly, for areas and parts of the world where COVID vaccines will not be made available or accessible, viable treatments need to be accessed for potential risks in order to provide the best alternatives. Link to Scientific Report article, NIH & FDA press releases from AnaBios; NIH/NCATS Awards SBIR Grant to AnaBios FDA Inks Research Collaboration with AnaBios FDA Awards AnaBios Contract This episode edited and produced by Margaret Beveridge.